Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Ipsen

Deal Watch: Menarini Enters US Oncology Market Via Merger With Stemline

Menarini/Stemline, Supernus/US WorldMeds, BioMarin/DiNOAQOR, Adicet/ResTORbio, Vertex/Affinia, Hansoh/NiKang, plus COVID-19 deals in brief and more.

Deals Business Strategies

Opdivo/Cabometyx Combo ‘Very Encouraging' In 1L RCC

Positive new top-line Phase III results look set to strengthen Opdivo combination therapy in first-line kidney cancer through an improved toxicity profile.

ImmunoOncology Clinical Trials

Ipsen’s Dysport Likely Impacted By COVID-19 In Q2, But China Sales To Return

Sales grew 9.6% at Ipsen in the first quarter, and the search for a new CEO is on track, but France’s specialty pharmaceutical company maintained its 2020 guidance suspension because of the uncertainty over the course of the COVID-19 pandemic.

Sales & Earnings Neurology

New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program

Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.

Orthopedics Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Gynecological, Urological
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Beaufour Ipsen
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Ipsen
  • Senior Management
  • Aymeric le Chatelier, EVP, Fin. & CFO & Interim CEO
    Alexandre Lebeaut, MD, EVP, R&D & CSO
    Ivana Magovcevic-Liebisch, EVP, CBO
    Steven Hildemann, MD, PhD, EVP, CMO
  • Contact Info
  • Ipsen
    Phone: (33) 1 58 33 50 00
    65 Quai George Gorse
    Boulogne-Billancourt, 92100
    France
UsernamePublicRestriction

Register